TY - JOUR
T1 - Absence of the Autophagy Adaptor SQSTM1/p62 Causes Childhood-Onset Neurodegeneration with Ataxia, Dystonia, and Gaze Palsy
AU - Haack, Tobias B B.
AU - Iuso, Arcangela
AU - Kremer, Laura S S.
AU - Hartig, Monika
AU - Strom, Tim M M.
AU - Meitinger, Thomas
AU - Prokisch, Holger
AU - Gorza, Matteo
AU - Graf, Elisabeth
AU - Berutti, Riccardo
AU - Ignatius, Erika
AU - Isohanni, Pirjo
AU - Suomalainen, Anu
AU - Carroll, Christopher J J.
AU - Lönnqvist, Tuula
AU - Calvo-Garrido, Javier
AU - Stranneheim, Henrik
AU - Wedell, Anna
AU - Maffezzini, Camilla
AU - Freyer, Christoph
AU - Wredenberg, Anna
AU - Paucar, Martin
AU - Svenningsson, Per
AU - Brandberg, Göran
AU - Kurian, Manju A A.
AU - Hayflick, Susan A A.
AU - Hayflick, Susan A A.
AU - Venco, Paola
AU - Tiranti, Valeria
AU - Dichgans, Martin
AU - Klopstock, Thomas
AU - Horvath, Rita
AU - Holinski-Feder, Elke
AU - Senderek, Jan
N1 - Funding Information:
We thank all the families for their participation and Dr. Boriana B?chner, Dr. Ivan Karin, and Dr. Benedikt Schoser for their support in phenotyping. This study was supported by the German Bundesministerium f?r Bildung und Forschung (BMBF) through the German Network for Mitochondrial Disorders (mitoNET; 01GM1113A-E to T.M., H.P., and T.K.), the E-Rare project GENOMIT (01GM1207 to T.M. and H.P.), the Juniorverbund in der Systemmedizin ?mitOmics? (FKZ 01ZX1405C to T.B.H.), as well as the European Commission 7th Framework Programme (FP7/2007-2013, HEALTH-F2-2011, grant agreement No. 277984, TIRCON). E.I. was supported by the Arvo and Lea Ylpp? Foundation, P.I. by Foundation for Pediatric Research, and C.J.C. by a Helsinki University research grant. A.S. acknowledges support of Sigrid Jus?lius Foundation, Aatos and Jane Erkko Foundation, and Academy of Finland. R.H. is a Wellcome Trust Investigator (109915/Z/15/Z) and was supported by the Medical Research Council (UK) (G1000848) and the European Research Council (309548). Additional support came from The Swedish Research Council (VR521-2012-2571 to A. Wredenberg and K2014-54X-20642-13-3 to A. Wedell), Stockholm County Council (K0176-2012 to A. Wredenberg and 20140053 to A. Wedell), Swedish Foundation for Strategic Research (ICA 12-0017 to A. Wredenberg), Knut & Alice Wallenberg Foundation (KAW 20130026 to A. Wredenberg and A. Wedell), and The Swedish Brain Foundation (FO2015-0146). A. Wredenberg is a Ragnar S?derberg fellow (M77/13). We acknowledge the ?Cell Lines and DNA Bank of Paediatric Movement Disorders and Neurodegenerative Diseases? of the Telethon Network of Genetic Biobanks (grant GTB12001J) and the Eurobiobank Network. This work was supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) within the framework of the Munich Cluster for Systems Neurology (EXC 1010 SyNergy) to T.M. and T.K.
Funding Information:
We thank all the families for their participation and Dr. Boriana Büchner, Dr. Ivan Karin, and Dr. Benedikt Schoser for their support in phenotyping. This study was supported by the German Bundesministerium für Bildung und Forschung (BMBF) through the German Network for Mitochondrial Disorders (mitoNET; 01GM1113A-E to T.M., H.P., and T.K.), the E-Rare project GENOMIT (01GM1207 to T.M. and H.P.), the Juniorverbund in der Systemmedizin “mitOmics” (FKZ 01ZX1405C to T.B.H.), as well as the European Commission 7th Framework Programme (FP7/2007-2013, HEALTH-F2-2011, grant agreement No. 277984, TIRCON). E.I. was supported by the Arvo and Lea Ylppö Foundation, P.I. by Foundation for Pediatric Research, and C.J.C. by a Helsinki University research grant. A.S. acknowledges support of Sigrid Jusélius Foundation, Aatos and Jane Erkko Foundation, and Academy of Finland. R.H. is a Wellcome Trust Investigator (109915/Z/15/Z) and was supported by the Medical Research Council (UK) (G1000848) and the European Research Council (309548). Additional support came from The Swedish Research Council (VR521-2012-2571 to A. Wredenberg and K2014-54X-20642-13-3 to A. Wedell), Stockholm County Council (K0176-2012 to A. Wredenberg and 20140053 to A. Wedell), Swedish Foundation for Strategic Research (ICA 12-0017 to A. Wredenberg), Knut & Alice Wallenberg Foundation (KAW 20130026 to A. Wredenberg and A. Wedell), and The Swedish Brain Foundation (FO2015-0146). A. Wredenberg is a Ragnar Söderberg fellow (M77/13). We acknowledge the “Cell Lines and DNA Bank of Paediatric Movement Disorders and Neurodegenerative Diseases” of the Telethon Network of Genetic Biobanks (grant GTB12001J) and the Eurobiobank Network. This work was supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) within the framework of the Munich Cluster for Systems Neurology (EXC 1010 SyNergy) to T.M. and T.K.
Publisher Copyright:
© 2016 American Society of Human Genetics
PY - 2016/9/1
Y1 - 2016/9/1
N2 - SQSTM1 (sequestosome 1; also known as p62) encodes a multidomain scaffolding protein involved in various key cellular processes, including the removal of damaged mitochondria by its function as a selective autophagy receptor. Heterozygous variants in SQSTM1 have been associated with Paget disease of the bone and might contribute to neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Using exome sequencing, we identified three different biallelic loss-of-function variants in SQSTM1 in nine affected individuals from four families with a childhood- or adolescence-onset neurodegenerative disorder characterized by gait abnormalities, ataxia, dysarthria, dystonia, vertical gaze palsy, and cognitive decline. We confirmed absence of the SQSTM1/p62 protein in affected individuals’ fibroblasts and found evidence of a defect in the early response to mitochondrial depolarization and autophagosome formation. Our findings expand the SQSTM1-associated phenotypic spectrum and lend further support to the concept of disturbed selective autophagy pathways in neurodegenerative diseases.
AB - SQSTM1 (sequestosome 1; also known as p62) encodes a multidomain scaffolding protein involved in various key cellular processes, including the removal of damaged mitochondria by its function as a selective autophagy receptor. Heterozygous variants in SQSTM1 have been associated with Paget disease of the bone and might contribute to neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Using exome sequencing, we identified three different biallelic loss-of-function variants in SQSTM1 in nine affected individuals from four families with a childhood- or adolescence-onset neurodegenerative disorder characterized by gait abnormalities, ataxia, dysarthria, dystonia, vertical gaze palsy, and cognitive decline. We confirmed absence of the SQSTM1/p62 protein in affected individuals’ fibroblasts and found evidence of a defect in the early response to mitochondrial depolarization and autophagosome formation. Our findings expand the SQSTM1-associated phenotypic spectrum and lend further support to the concept of disturbed selective autophagy pathways in neurodegenerative diseases.
UR - http://www.scopus.com/inward/record.url?scp=84996806746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996806746&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2016.06.026
DO - 10.1016/j.ajhg.2016.06.026
M3 - Article
C2 - 27545679
AN - SCOPUS:84996806746
SN - 0002-9297
VL - 99
SP - 735
EP - 743
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 3
ER -